Premium
The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof‐of‐Concept Clinical Study
Author(s) -
Hadjidemetriou Marilena,
McAdam Sarah,
Garner Grace,
Thackeray Chelsey,
Knight David,
Smith Duncan,
AlAhmady Zahraa,
Mazza Mariarosa,
Rogan Jane,
Clamp Andrew,
Kostarelos Kostas
Publication year - 2019
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201803335
Subject(s) - in vivo , biomolecule , nanomedicine , liposome , biophysics , materials science , blood proteins , ex vivo , corona (planetary geology) , nanotechnology , proteome , nanoparticle , chemistry , biochemistry , biology , microbiology and biotechnology , astrobiology , venus
The self‐assembled layered adsorption of proteins onto nanoparticle (NP) surfaces, once in contact with biological fluids, is termed the “protein corona” and it is gradually seen as a determinant factor for the overall biological behavior of NPs. Here, the previously unreported in vivo protein corona formed in human systemic circulation is described. The human‐derived protein corona formed onto PEGylated doxorubicin‐encapsulated liposomes (Caelyx) is thoroughly characterized following the recovery of liposomes from the blood circulation of ovarian carcinoma patients. In agreement with previous investigations in mice, the in vivo corona is found to be molecularly richer in comparison to its counterpart ex vivo corona. The intravenously infused liposomes are able to scavenge the blood pool and surface‐capture low‐molecular‐weight, low‐abundance plasma proteins that cannot be detected by conventional plasma proteomic analysis. This study describes the previously elusive or postulated formation of protein corona around nanoparticles in vivo in humans and illustrates that it can potentially be used as a novel tool to analyze the blood circulation proteome.